TRANEXAMIC ACID INJECTION 100 MG — DIN 02466015
TRANEXAMIC ACID : 100 MG · AURO PHARMA INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is TRANEXAMIC ACID INJECTION?
TRANEXAMIC ACID INJECTION 100 MG contains TRANEXAMIC ACID : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02466015, held by AURO PHARMA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 09-Jun-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRANEXAMIC ACID INJECTION used for?
Increased local fibrinolysis when the diagnosis is indicative of hyperfibrinolysis, such as dental extraction in patients with coagulopathies (in conjunction with antihaemophilic factor).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Tranexamic Acid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
15 holders have a Canadian DIN containing Tranexamic Acid, across 23 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 2 | 2 | TRANEXAMIC ACID, TRANEXAMIC ACID INJECTION | Sourceable in Canada |
| PFIZER CANADA ULC | 2 | 2 | CYKLOKAPRON 100 MG/ML, CYKLOKAPRON 500 MG | Sourceable in Canada |
| AURO PHARMA INC | 3 | 1 | TRANEXAMIC ACID INJECTION | Sourceable in Canada |
| EUGIA PHARMA INC. | 2 | 1 | TRANEXAMIC ACID INJECTION | Sourceable in Canada |
| GENMED A DIVISION OF PFIZER CANADA ULC | 2 | 1 | GD-TRANEXAMIC ACID | Sourceable in Canada |
| STERIMAX INC | 2 | 1 | TRANEXAMIC ACID INJECTION BP, TRANEXAMIC ACID TABLETS | Sourceable in Canada |
| MANTRA PHARMA INC | 1 | 1 | M-TRANEXAMIC ACID | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 1 | 1 | MAR-TRANEXAMIC ACID | Sourceable in Canada |
| OMEGA LABORATORIES LIMITED | 1 | 1 | TRANEXAMIC ACID INJECTION | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | TRANEXAMIC ACID INJECTION BP | Sourceable in Canada |
| BAXTER CORPORATION | 2 | 0 | TRANEXAMIC ACID INJECTION, USP | No marketed DIN |
| FERRING INC | 1 | 0 | LYSTEDA | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 5 mL and 10 mL single-use ampoules (10 per carton); 5 mL, 10 mL vials (10 per carton); 50 mL pharmacy bulk vials (1 per carton). |
| Storage | Mixtures with compatible diluents should be used immediately or stored at 2 – 8°C for a maximum of 24 hours. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Tranexamic Acid |
|---|---|
| ATC code | B02AA02 |
| AHFS class | 20:28.16 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02466015 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2466015 |
| Brand name | TRANEXAMIC ACID INJECTION |
| Generic / active ingredient | TRANEXAMIC ACID : 100 MG |
| Market authorization holder | AURO PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | B02AA02 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B02AA |
| Current status | MARKETED |
| Status date | 09-Jun-2021 |
| Original market date | 2021-06-09 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Dental surgery: 10 mg/kg IV 2 hours pre-op. Administer by slow IV injection (50 mg/min). Dosage adjustment required for renal impairment based on serum creatinine levels.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Intrathecal/epidural admin; history/risk of thrombosis; active thromboembolic disease; acquired color vision disturbances; subarachnoid haemorrhage; haematuria; hypersensitivity.
Warnings and precautions
Erroneous intrathecal/epidural admin can be fatal. Risk of venous/arterial thrombosis. Convulsions reported. Visual disturbances may occur; regular ophthalmic check-ups advised for long-term use.
Is Tranexamic Acid in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 23 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CYKLOKAPRON 100 MG/ML | 100 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02064413 |
| CYKLOKAPRON 500 MG | 500 MG | TABLET | PFIZER CANADA ULC | MARKETED | 02064405 |
| GD-TRANEXAMIC ACID | 500 MG | TABLET | GENMED A DIVISION OF PFIZER CANADA ULC | MARKETED | 02409097 |
| M-TRANEXAMIC ACID | 500 MG | TABLET | MANTRA PHARMA INC | MARKETED | 02549395 |
| MAR-TRANEXAMIC ACID | 500 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | 02496232 |
| TRANEXAMIC ACID | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02519194 |
| TRANEXAMIC ACID INJECTION | 100 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | 02531194 |
| TRANEXAMIC ACID INJECTION | 100 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | 02392763 |
| TRANEXAMIC ACID INJECTION | 100 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02497328 |
| TRANEXAMIC ACID INJECTION BP | 100 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02246365 |
2 · Same class — other molecules in ATC B02AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tranexamic Acid | CYKLOKAPRON 100 MG/ML · CYKLOKAPRON 500 MG · ERFA-TRANEXAMIC · GD-TRANEXAMIC ACID · +8 more | 23 | 12 | Yes |
| Aminocaproic Acid | AMICAR - SYR 250MG/ML · AMICAR - TAB, 500MG · AMICAR INJ 250MG/ML · AMICAR INJECTION - LIQ IV 250MG/ML · +2 more | 6 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B02AB | Alfa1 Antitrypsin · Aprotinin | 12 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.